Anti-Human NT-proBNP
CAPTURE DETECTION APPLICATION LIMIT OF DETECTION
IDEAL APPLICATORS
BN1240 BN1241
CLIA
7 pg/mL
High-throughput clinical diagnostics
a.
2
1
COMPARATIVE CORRELATION CLIA | Meridian & Roche
COMPARATIVE CORRELATION CLIA | Meridian & Roche
y = 0.9998x - 0.4563 R 2 = 1
y = 0.9963x + 101.93 R 2 = 0.99
Roche (pg/mL)
Roche (pg/mL)
[ 1 ] Correlation between Meridian NT-proBNP antibody pair ( BN1240 and BN1241 ) and the Roche Elecsys ® proBNP II assay (Cobas e411) using the Bio-Rad NT-proBNP reference panel (human serum-based, multi-analyte control). [ 1a ] Overall correlation across concentrations up to approximately 3,400 pg/mL. [ 1b ] Expanded view of the lower concentration range (up to 140 pg/mL), demonstrating the strong correlation between antibody pair BN1240 & BN1241 and the Roche reference method at low NT-proBNP levels. [ 2 ] Correlation between Meridian NT-proBNP antibody pair ( BN1240 & BN1241 ) and the Roche Elecsys ® proBNP II (Cobas e411) using clinical samples ( ~ 30-30,000 pg/mL, R 2 = 0.99 ).
b.
y = 1.2111x - 6.7141 R 2 = 0.98
Roche (pg/mL)
CAPTURE DETECTION APPLICATION LIMIT OF DETECTION
IDEAL APPLICATORS
1 CLIA
55 pg/mL
High-throughput clinical diagnostics Point-of-care, multiplex panels
BN1240 BN1242
Serum: 112 pg/mL Whole Blood: 60 pg/mL
2 FIA
COMPARATIVE CORRELATION CLIA | Meridian & Roche 1
FIA | Meridian & Roche 2
COMPARATIVE CORRELATION
y = 0.7875x — 54.703 R 2 = 0.96
y = 1.3086x + 570.1 R 2 = 0.93
Roche (pg/mL)
Roche (pg/mL)
[ 1 ] Correlation between Meridian NT-proBNP antibodies ( BN1240 & BN1242 ) in a CLIA assay and the Roche Elecsys ® proBNP II (Cobas e411) using clinical samples. The assay demonstrated a linear correlation ( R 2 = 0.96 ) with the Roche reference method.
[ 2 ] Correlation between Meridian NT-proBNP antibodies ( BN1240 & BN1242 ) in a FIA assay and the Roche Elecsys ® proBNP II (Cobas e411) using clinical samples. The assay demonstrated a linear correlation ( R 2 = 0.93 ) with the Roche reference method.
Powered by FlippingBook